FLEXICORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLEXICORT (FLEXICORT).
FLEXICORT contains the active ingredient prednisolone, a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression, inhibition of phospholipase A2, and suppression of inflammatory mediators such as prostaglandins and leukotrienes.
| Metabolism | Prednisolone is primarily metabolized in the liver via reduction and conjugation, with CYP3A4 playing a minor role. The major metabolite is inactive prednisone. |
| Excretion | Renal excretion of inactive metabolites accounts for 95% of elimination; biliary/fecal excretion is minimal at 5%. |
| Half-life | 8–12 hours; clinical context: once-daily dosing maintains therapeutic levels, with steady-state achieved within 2–3 days. |
| Protein binding | 90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | 0.5–0.7 L/kg; clinical meaning: moderate distribution indicates extensive tissue penetration, especially into inflamed tissues. |
| Bioavailability | Oral: 70–80%; Topical: 2–5% (varies with formulation and skin integrity). |
| Onset of Action | Oral: 1–2 hours; IV: 15–30 minutes; Topical: 2–4 hours. |
| Duration of Action | 24–36 hours for anti-inflammatory effect; clinical notes: duration allows once-daily dosing for chronic conditions. |
| Molecular Weight | 470.53 |
Flexicort is not a recognized drug name in authoritative pharmacological databases. Please verify the correct generic name. Assuming hydrocortisone: Typical adult dose is 10-40 mg orally daily in divided doses or as a single morning dose. Route: oral. Frequency: once or twice daily.
| Dosage form | CREAM |
| Renal impairment | No specific GFR-based dose adjustment for hydrocortisone. Use with caution in severe renal impairment due to fluid retention. |
| Liver impairment | In Child-Pugh class B or C, reduce dose by 50% of normal or use with caution due to reduced metabolism. |
| Pediatric use | For hydrocortisone: 0.5-2 mg/kg/day orally in divided doses every 6-8 hours, not to exceed 50 mg/m²/day. |
| Geriatric use | Start at the lower end of the dosing range (10-20 mg/day) due to potential for increased risk of osteoporosis, hypertension, and glucose intolerance. |
| 1st trimester | Avoid: First-trimester use is contraindicated due to risk of cleft palate and other congenital malformations. Corticosteroids are category C/D. |
| 2nd trimester | Cautious use: Potential risks of intrauterine growth restriction and hypothalamic-pituitary-adrenal axis suppression in fetus. Use only if benefit outweighs risk. |
| 3rd trimester | Cautious use: Risk of neonatal adrenal suppression. Avoid high doses near term. |
Clinical note
Comprehensive clinical and safety monograph for FLEXICORT (FLEXICORT).
| Placental transfer | Corticosteroids cross the placenta. Fetal exposure depends on maternal dose and bioavailability. Betamethasone and dexamethasone cross more readily, but for other corticosteroids, transfer is variable. |
| Breastfeeding | FLEXICORT is excreted into breast milk in low quantities. However, with high maternal doses, potential for growth suppression or adrenal suppression in the nursing infant exists. Monitoring infant growth and development is recommended. |
■ FDA Black Box Warning
Long-term use of corticosteroids, including FLEXICORT, is not recommended due to the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression and potential for adrenal crisis upon withdrawal.
| Serious Effects |
Systemic fungal infectionConcurrent vaccination with live vaccinesHypersensitivity to any component
| Precautions | HPA axis suppression and adrenal insufficiency upon withdrawal, Increased risk of infections, Masking of signs of infection, Gastrointestinal perforation or bleeding, Cushing's syndrome with chronic use, Osteoporosis with long-term therapy, Growth suppression in children, Ocular effects (cataracts, glaucoma, central serous chorioretinopathy), Psychiatric disturbances (euphoria, depression, psychosis) |
| Food/Dietary | No significant food interactions. Take with food if gastrointestinal upset occurs with oral formulations. Topical use has no dietary restrictions. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Associated with increased risk of orofacial clefts (odds ratio ~1.3-3.3). Second/third trimester: Prolonged use may cause fetal adrenal suppression, intrauterine growth restriction, and premature birth. Avoid high doses near term due to risk of neonatal adrenal insufficiency. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of adrenal suppression. Fetal ultrasound for growth restriction if prolonged use. Neonatal monitoring for adrenal insufficiency after delivery if maternal use in third trimester. |
| Fertility Effects | May inhibit gonadotropin release, potentially impairing ovulation/fertility at high doses. Effects are dose-dependent and typically reversible upon discontinuation. |
| Clinical Pearls | Flexicort (hydrocortisone acetate 1% cream) is a low-potency topical corticosteroid suitable for mild inflammatory dermatoses. Avoid use on face, groin, axillae, or intertriginous areas due to risk of skin atrophy. Limit continuous use to 2 weeks. Do not use under occlusive dressings unless directed. Monitor for signs of secondary infection. In children, use only smallest amount needed due to higher systemic absorption. |
| Patient Advice | Apply a thin layer only to affected areas, not to normal skin. · Do not use longer than 2 weeks unless instructed by your doctor. · Avoid contact with eyes, mouth, or broken skin. · Do not cover the treated area with bandages or wraps unless told to do so. · Wash hands after application unless treating hands. · If you get the cream in your eyes, rinse with plenty of water and seek medical attention if irritation persists. · Report any signs of skin thinning, infection, or worsening of condition to your doctor. · Keep out of reach of children. |